Event-Driven Stocks

89bio, Inc.

ETNB

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 1 warning● 2 severedetails ↓

Financials

SEC XBRL · annual
 FY24FY23FY22FY21FY20FY19
Revenue——————
Operating income−$384.7M−$151.2M−$102.2M−$89.7M−$49.4M−$26.6M
Net income−$367.1M−$142.2M−$102.0M−$90.1M−$49.5M−$57.4M
Total assets$478.7M$596.3M$196.8M$162.4M$211.1M$95.6M
Total liabilities$77.9M$60.0M$45.0M$36.5M$8.1M—
Equity$400.8M$536.3M$151.8M$126.0M$203.0M$89.9M
EPS (diluted)$-3.51$-2.00$-2.93$-4.48——
Shares out.93.5M52.2M20.4M19.9M13.8M13.8M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2024
Operating margin
—
Net margin
—
Return on equity
−91.6%
Return on assets
−76.7%
Return on capital (ROCE)
−86.9%
Liabilities / assets
16.3%
Debt / equity
0.19×
Book value / share
$4.29
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2024
Altman Z″ (distress)
0.42distress
Accruals / assets
0.2%clean
Piotroski F-Score
0/7weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
35
/ 100
Profitability 0Growth n/aCatalyst 33Earnings quality 33Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 severe● 1 warning● 2 good
  • Altman Z″ in the distress zone
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
Oct 15, 20256.8M1.9-22.4%
Sep 30, 20258.7M1.0-43.3%
Sep 15, 202515.4M12.4-6.2%
Aug 29, 202516.4M11.7+5.0%
Aug 15, 202515.6M9.1-1.1%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)